Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: A systematic review

Future Oncology

Volumn 12, Issue 10, 2016, Pages 1299-1307

  Rossi, Sabrina ^a   Schinzari, Giovanni ^a   Basso, Michele ^a   Strippoli, Antonia ^a   Dadduzio, Vincenzo ^a   D'Argento, Ettore ^a   Cassano, Alessandra ^a   Barone, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

chemotherapy; endocrine treatment; maintenance therapy; metastatic breast cancer

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FLUOXYMESTERONE; FULVESTRANT; GEMCITABINE; IFOSFAMIDE; LETROZOLE; LONIDAMINE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHOTREXATE; NAVELBINE; PACLITAXEL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAXANE DERIVATIVE; THALIDOMIDE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; DISEASES; DRUG EFFICACY; DRUG SAFETY; HORMONAL THERAPY; HUMAN; MAINTENANCE CHEMOTHERAPY; MAINTENANCE HORMONE THERAPY; MAINTENANCE THERAPY; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPTOM; SYSTEMATIC REVIEW; TIME TO PROGRESSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; MORTALITY; PROCEDURES;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; QUALITY OF LIFE;

EID: 84965172417     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon-2015-0065     Document Type: Article

References (34)

1. Gennari A, Stockler M, Puntoni M., et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-Analysis of randomized clinical trials. J. Clin. Oncol. 29(16), 2144-2149 (2011).
2. Dufresne A, Pivot X, Tournigand C., et al. Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer. Int. J. Med. Sci. 5(2), 100-105 (2008).
3. Berruti A, Zola P, Buniva T., et al. Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival. Anticancer Res. 17(4A), 2763-2768 (1997).
4. Kloke O, Klaassen U, Oberhoff C., et al. Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group. Breast Cancer Res. Treat. 55(1), 51-59 (1999).
5. Bertelli G, Garrone O, Bertolotti L., et al. Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer. Oncology 68(4-6), 364-370 (2005).
6. Catania C, Ascione G, Adamoli L., et al. Fulvestrant in heavily pre-Treated patients with advanced breast cancer: results from a single compassionate use programme centre. Breast Cancer Res. Treat. 106(1), 97-103 (2007).
7. Lim S, Lee S, Han J., et al. Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer. Breast 22(6), 1205-1209 (2013).
8. Montemurro F, Rondón G, Ueno NT, Munsell M, Gajewski JL, Champlin RE. Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy. Bone Marrow Transplant 29(10), 861-866 (2002).
9. Fabi A, Russillo M, Ferretti G., et al. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer 12, 482 (2012).
10. Redondo A, Martínez V, Zamora P., et al. Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer. Onco Targets Ther. 7, 2175-2181 (2014).
11. Carillio G, Scandurra G, Aiello R., et al. Fulvestrant in metastatic breast cancer: safety, efficacy, and role as mainteinance therapy for heavily pretreated patients. J. Clin. Oncol. 26(15S), 1133 (2008).
12. Rowlings PA, Williams SF, Antman KH., et al. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA 282(14), 1335-1343 (1999).
13. Miller K, Wang M, Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357(26), 2666-2676 (2007).
14. Miles DW, Chan A, Dirix LY., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28(20), 3239-3247 (2010).
15. Robert NJ, Diéras V, Glaspy J., et al. RIBBON-1: randomized, double-blind, placebo-controlled, Phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 29(10), 1252-1260 (2011).
16. Manders P, Beex LV, Tjan-Heijnen VC., et al. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer 98(10), 2125-2132 (2003).
17. Marcom PK, Isaacs C, Harris L., et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res. Treat. 102(1), 43-49 (2007).
18. Coates A, Gebski V, Bishop JF., et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N. Engl. J. Med. 317(24), 1490-1495 (1987).
19. Gregory RK, Powles TJ, Chang JC, Ashley S. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur. J. Cancer 33(13), 2194-2197 (1997).
20. Muss HB, Case LD, Richards F 2nd., et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N. Engl. J. Med. 325(19), 1342-1348 (1991).
21. Falkson G, Gelman RS, Pandya KJ., et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J. Clin. Oncol. 16(5), 1669-1676 (1998).
22. Colleoni M, Rocca A, Sandri MT., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 13(1), 73-80 (2002).
23. Colleoni M, Orlando L, Sanna G., et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann. Oncol. 17(2), 232-238 (2006).
24. Nooij MA, de Haes JC, Beex LV., et al. Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: clinical outcomes and oncologists preferences. Eur. J. Cancer 39(5), 614-621 (2003).
25. Lv H, Yan M, Zhang M, Niu L, Zeng H, Cui S. Efficacy of capecitabine-based combination therapy and single-Agent capecitabine maintenance therapy in patients with metastatic breast cancer. Chin. J. Cancer Res. 26(6), 692-697 (2014).
26. Liang X, Yan Y, Wang L., et al. First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients. Oncol. Lett. 9(2), 987-993 (2015).
27. Segura-González M, Quintana-Quintana M. Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute. Med. Oncol. 32(4), 93 (2015).
28. Gligorov J, Doval D, Bines J., et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, Phase 3 trial. Lancet Oncol. 15(12), 1351-1360 (2014).
29. Alba E, Ruiz-Borrego M, Margelí M., et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-2001 study. Breast Cancer Res. Treat. 122(1), 169-176 (2010).
30. Gennari A, Amadori D, De Lena M., et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J. Clin. Oncol. 24(24), 3912-3918 (2006).
31. Park YH, Jung KH, Im SA., et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J. Clin. Oncol. 31(14), 1732-1739 (2013).
32. Becher R, Kloke O, Hayungs J., et al. Epirubicin and ifosfamide in metastatic breast cancer. Semin. Oncol. 23(3 Suppl. 7), 28-33 (1996).
33. Ejlertsen B, Pfeiffer P, Pedersen D., et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur. J. Cancer 29A(4), 527-531 (1993).
34. French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J. Clin. Oncol. 18(17), 3115-3124 (2000).